Browse Health


Education ?

Medical School
Medical University - Varna (1997)
Foreign school

Awards & Distinctions ?

Patients' Choice Award (2008 - 2009)
Bridges to Excellence Recognition
Diabetes Care Recognition (2015 - 2017)
Level II
American Board of Internal Medicine
American Association of Clinical Endocrinologists

Affiliations ?

Dr. Kaloyanova is affiliated with 3 hospitals.

Hospital Affiliations



  • Medical City Dallas Hospital
    7777 Forest Ln, Dallas, TX 75230
    Top 25%
  • North Central Medical Center
    4500 Medical Center Dr, McKinney, TX 75069
    Top 50%
  • Medical City
  • Publications & Research

    Dr. Kaloyanova has contributed to 2 publications.
    Title Insulin-based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes: Which is Better?
    Date December 2009
    Journal Diabetes Care

    Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL).

    Title Insulin As Initial Therapy in Type 2 Diabetes: Effective, Safe, and Well Accepted.
    Date April 2008
    Journal Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research

    BACKGROUND: To achieve glycemic control in type 2 diabetes mellitus (T2DM), multiple oral agents are used in a stepwise approach, but long-term maintenance of normoglycemia is difficult to achieve, and, eventually, most patients require insulin. The aim of this study was to evaluate the feasibility, acceptability, and efficacy of insulin with metformin for newly diagnosed, treatment-naive patients with T2DM. METHODS: Eligible patients were started on insulin NovoLog 70/30 and metformin 1,000 mg twice daily. Biochemical evaluation was performed at baseline and at the end of the 3-month study. Patients were seen monthly to assess side effects and compliance and make insulin dose adjustments. Patient treatment satisfaction was evaluated at the end of the study. RESULTS: Of 63 patients, 92% completed the study. The hemoglobin A(1c) (HbA(1c)) decreased from 10.8 to 5.9% (p < .0001), and 100% of subjects achieved an HbA(1)c < 7%. Weight increased from 100.0 to 101.6 kg (p = .004) but was less than expected given that patients lost an average of 7.2 kg prior to diagnosis and achieved a reduction in HbA(1c) of 5%. The rate of hypoglycemia was low (1.5 episodes/patient-month). Ninety-seven percent of the patients were satisfied with their insulin treatment, and 88% were willing to continue insulin. Compliance was 96.5% with insulin and 95.1% with metformin. CONCLUSION: Outpatient initiation of insulin therapy at the time of diagnosis of T2DM is an effective, safe, and feasible strategy for rapidly lowering HbA(1c) levels to targets. Insulin was very well accepted by the patients, refuting the misconception of low satisfaction and acceptance of such treatment.

    Similar doctors nearby

    Dr. Ellen Sher

    22 years experience
    Dallas, TX

    Dr. Salomon Banarer

    Internal Medicine
    17 years experience
    Dallas, TX

    Dr. Noel Peng

    Obstetrics & Gynecology
    16 years experience
    Dallas, TX

    Dr. Walid Saleh

    Obstetrics & Gynecology
    26 years experience
    Dallas, TX

    Dr. Brian Cohen

    Obstetrics & Gynecology
    46 years experience
    Dallas, TX

    Dr. David Feinstein

    Endocrinology, Diabetes & Metabolism
    39 years experience
    Dallas, TX
    Search All Similar Doctors